NO933960L - Interleukin receptor targeting molecules for the treatment of inflammatory arthritis - Google Patents

Interleukin receptor targeting molecules for the treatment of inflammatory arthritis

Info

Publication number
NO933960L
NO933960L NO933960A NO933960A NO933960L NO 933960 L NO933960 L NO 933960L NO 933960 A NO933960 A NO 933960A NO 933960 A NO933960 A NO 933960A NO 933960 L NO933960 L NO 933960L
Authority
NO
Norway
Prior art keywords
inflammatory arthritis
treatment
targeting molecules
receptor targeting
interleukin receptor
Prior art date
Application number
NO933960A
Other languages
Norwegian (no)
Other versions
NO933960D0 (en
Inventor
Thasia G Woodworth
Jean C Nichols
Patricia A Bacha
Original Assignee
Seragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seragen Inc filed Critical Seragen Inc
Publication of NO933960D0 publication Critical patent/NO933960D0/en
Publication of NO933960L publication Critical patent/NO933960L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Abstract

Oppfinnelsen vedrører en metode for å behandle en pasient med inflammatorisk artritis, hvilken metode medfører å administrere til pasienten et molekyl som er i stand til å spesifikt binde til en proteinaktig cellereseptor uttrykt på en lymfocytt hos pasienten, og som bidrar til pasientens inflammatoriske artritis, idet molekylet ;er i stand til å redusere lymfocyttens levedyktighet.The invention relates to a method of treating a patient with inflammatory arthritis, which method of administering to the patient a molecule capable of specifically binding to a proteinaceous cell receptor expressed on a lymphocyte of the patient and contributing to the patient's inflammatory arthritis, The molecule is capable of reducing the viability of the lymphocyte.

NO933960A 1991-05-03 1993-11-02 Interleukin receptor targeting molecules for the treatment of inflammatory arthritis NO933960L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69548091A 1991-05-03 1991-05-03
US87652192A 1992-04-30 1992-04-30
PCT/US1992/003714 WO1992019259A1 (en) 1991-05-03 1992-05-04 Interleukin receptor targeted molecules for treatment of inflammatory arthritis

Publications (2)

Publication Number Publication Date
NO933960D0 NO933960D0 (en) 1993-11-02
NO933960L true NO933960L (en) 1993-12-28

Family

ID=27105578

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933960A NO933960L (en) 1991-05-03 1993-11-02 Interleukin receptor targeting molecules for the treatment of inflammatory arthritis

Country Status (7)

Country Link
EP (1) EP0668774A1 (en)
JP (1) JPH06510750A (en)
AU (1) AU665763B2 (en)
BR (1) BR9205967A (en)
CA (1) CA2108886A1 (en)
NO (1) NO933960L (en)
WO (1) WO1992019259A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP4011915B8 (en) 2012-08-21 2023-11-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
TWI697334B (en) 2013-06-04 2020-07-01 美商再生元醫藥公司 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
TWI634900B (en) 2013-07-11 2018-09-11 再生元醫藥公司 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
AU2015222951B2 (en) 2014-02-28 2020-06-11 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an IL-4R antagonist
RU2734490C2 (en) 2014-11-14 2020-10-19 Санофи Байотекнолоджи Methods of treating chronic sinusitis with nasal polyps by administering il-4r antagonist
MX2019002344A (en) 2016-09-01 2019-09-06 Regeneron Pharma Methods for preventing or treating allergy by administering an il-4r antagonist.
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
TW202332696A (en) 2016-12-01 2023-08-16 美商再生元醫藥公司 Methods of treating inflammatory conditions
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
AU2018359219A1 (en) 2017-10-30 2020-04-23 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing asthma by administering an IL-4R antagonist
SG11202009371WA (en) 2018-05-13 2020-10-29 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r inhibitor
CN113597328A (en) 2019-03-21 2021-11-02 瑞泽恩制药公司 Combination of an IL-4/IL-13 pathway inhibitor and plasma cell ablation for the treatment of allergy
MX2022001030A (en) 2019-08-05 2022-04-26 Regeneron Pharma Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE448386B (en) * 1978-10-18 1987-02-16 Sandoz Ag NEW CYCLOSPORIN DERIVATIVES, PROCEDURE FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
US5080898A (en) * 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
ES8407097A1 (en) * 1982-05-12 1984-08-16 Harvard College Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof.
IL89504A0 (en) * 1988-03-08 1989-09-10 Univ Wyoming Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same
WO1992006117A1 (en) * 1990-09-28 1992-04-16 Seragen, Inc. Inhibiting unwanted immune responses

Also Published As

Publication number Publication date
NO933960D0 (en) 1993-11-02
CA2108886A1 (en) 1992-11-04
EP0668774A4 (en) 1995-04-25
WO1992019259A1 (en) 1992-11-12
AU1992792A (en) 1992-12-21
BR9205967A (en) 1994-07-26
EP0668774A1 (en) 1995-08-30
AU665763B2 (en) 1996-01-18
JPH06510750A (en) 1994-12-01

Similar Documents

Publication Publication Date Title
NO933960L (en) Interleukin receptor targeting molecules for the treatment of inflammatory arthritis
FI941022A0 (en) Spirocyclic piperidine derivatives
BG103179A (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
NO933171L (en) Use of molecules targeting cell surface receptors for the treatment of viral diseases
AP9701041A0 (en) Pyridylpyrrole compounds.
DK0705244T3 (en) Nitro-amino acid disulfide for the treatment of diseases of the cardiovascular system
EE9900481A (en) Small molecules used to treat inflammatory diseases
DK0660705T3 (en) Advanced drug delivery system and method for treating psychiatric, neurological and other disorders with approx.
DK0867184T3 (en) Use of tiagabine for the treatment of sleep disorders
NO20041166L (en) Use of optically pure (+) norcisapride in combination with another therapeutic agent for the manufacture of a drug
NZ301645A (en) (R)-(-)-methyl phenyl oxazolidinone derivatives, pharmaceutical preparations and use for treating TNF stimulated diseases
IL126110A0 (en) Use of aryl n-substituted carboxamides to kill tumors and novel compounds for such use
NO981204D0 (en) Selective <beta> 3 -adrenergic agonists
ATE199829T1 (en) META SUBSTITUTED ARYLALKYLAMINES AND THERAPEUTIC AND DIAGNOSTIC USE THEREOF
WO2000071520A3 (en) Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors
DK0792162T3 (en) Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
PL310950A1 (en) Novel imidazole quinoxalinones, method of obtaining them and their application
ATE245991T1 (en) TREATMENT OF CHRONIC INFLAMMATORY DISEASES WITH CM101/GBS TOXIN
DK7286A (en) OCTAHYDROINDOLIZINER
AU4530796A (en) Treating disorders characterised by excessive cell proliferation with sclareolide
DK0658117T3 (en) Treatment of tumors with neurotrophic factors and cell proliferation inhibitors
FR2672888B1 (en) NEW UREAS AND THIOUREAS, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS.
DK0660825T3 (en) Anti-inflammatory macrolactams (cyclamenol)
UA30659A (en) Method for reduction of drug dependence